tetano
Editor, Senior Moderator
Infect Dis Ther
. 2020 Jul 10.
doi: 10.1007/s40121-020-00318-1. Online ahead of print.
That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19
Matthew R Davis[SUP] 1 [/SUP], Erin K McCreary[SUP] 2 [/SUP], Jason M Pogue[SUP] 3 [/SUP]
Affiliations
Abstract
Remdesivir is a nucleoside antiviral recently studied in several randomized trials for treatment of COVID-19. The available observational and prospective data are conflicting, requiring clinicians to critically evaluate and reconcile results to determine patient populations that may optimally benefit from remdesivir therapy, especially while drug supply is scarce. In this review, we analyze pertinent clinical remdesivir data for patients with COVID-19 from January 1, 2020, through May 31, 2020.
Keywords: ACTT-1; Antiviral; COVID-19; Coronavirus disease 2019; Remdesivir; SARS-CoV-2.
. 2020 Jul 10.
doi: 10.1007/s40121-020-00318-1. Online ahead of print.
That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19
Matthew R Davis[SUP] 1 [/SUP], Erin K McCreary[SUP] 2 [/SUP], Jason M Pogue[SUP] 3 [/SUP]
Affiliations
- PMID: 32651941
- DOI: 10.1007/s40121-020-00318-1
Abstract
Remdesivir is a nucleoside antiviral recently studied in several randomized trials for treatment of COVID-19. The available observational and prospective data are conflicting, requiring clinicians to critically evaluate and reconcile results to determine patient populations that may optimally benefit from remdesivir therapy, especially while drug supply is scarce. In this review, we analyze pertinent clinical remdesivir data for patients with COVID-19 from January 1, 2020, through May 31, 2020.
Keywords: ACTT-1; Antiviral; COVID-19; Coronavirus disease 2019; Remdesivir; SARS-CoV-2.